ArticleAmerican journal of hematology2021
Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis.
Abstract readLetter
In one paragraph
Article in American journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis.Leukemia · 2024Trial
- Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent/refractory adult Langerhans cell histiocytosis.Leukemia · 2022Trial
- Clinicopathological features of gastric Langerhans cell histiocytosis and a literature review.Journal of clinical and experimental hematopathology : JCEH · 2026Review
- RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition.Cancer cell · 2026Article
- Refractory Tumorous and Neurodegenerative Histiocytosis Treated With Intra-Arterial Chemotherapy.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Article
- Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France.Blood advances · 2025Article
- [Chinese expert consensus on the diagnosis and treatment of adult Langerhans cell histiocytosis (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Current State of Targeted Therapy in Adult Langerhans Cell Histiocytosis and Erdheim-Chester Disease.Targeted oncology · 2024Review
- Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures.Cancer · 2024Review
- Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy.British journal of haematology · 2024Article
- Continuous flow biocatalysis: synthesis of purine nucleoside esters catalyzed by lipase TL IM fromRSC advances · 2024Article
- Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms.British journal of haematology · 2023Article
- Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH.Blood advances · 2023Article
- Adult Onset Langerhans Cell Histiocytosis: Clinical Characteristics and Treatment Outcomes.Clinical hematology international · 2023Article
- Neurological Manifestations of Histiocytic Disorders.Current neurology and neuroscience reports · 2023Review
- CLIPPERS Responsive to Cladribine as a Durable Steroid-Sparing Agent.Neurology(R) neuroimmunology & neuroinflammation · 2023Article
- Article
- Adult Langerhans Cell Histiocytosis and the Skeleton.Journal of clinical medicine · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Gaurav GoyalDivision of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, Alabama.ORCID 0000-0001-6148-5177
Jithma P AbeykoonDivision of Hematology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0003-3939-6252
Marie HuDepartment of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, Minnesota.
Jason R YoungDepartment of Radiology, Mayo Clinic, Rochester, Minnesota.
Mithun V ShahDivision of Hematology, Mayo Clinic, Rochester, Minnesota.
N Nora BennaniDivision of Hematology, Mayo Clinic, Rochester, Minnesota.
Timothy G CallDivision of Hematology, Mayo Clinic, Rochester, Minnesota.
C Christopher HookDivision of Hematology, Mayo Clinic, Rochester, Minnesota.
Animesh PardananiDivision of Hematology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-9084-4148
David J InwardsDivision of Hematology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-6894-9277
Robert VassalloDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota.
Jay H RyuDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-9576-2272
W Oliver TobinDepartment of Neurology, Mayo Clinic, Rochester, Minnesota.
Matthew J KosterDivision of Rheumatology, Mayo Clinic, Rochester, Minnesota.
Caroline J Davidge-PittsDivision of Endocrinology, Diabetes, and Nutrition, Mayo Clinic, Rochester, Minnesota.
Aishwarya RavindranDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0003-4503-440X
Karen L RechDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Ronald S GoDepartment of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, Minnesota.
Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group
Funding
The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI WEINER, GEORGE J. · 2002 to 2021
$45.7MPaul Calabresi Program in Clinical/Translational Research at Mayo ClinicK12CA090628 · NCI · MAYO CLINIC ROCHESTER · PI WEROHA, SARAVUT · 2001 to 2025
$19.7MDiagnosis of indeterminate brain lesions using MRI-based machine learning and polygenic risk modelsR01NS113803 · NINDS · MAYO CLINIC ROCHESTER · PI ECKEL PASSOW, JEANETTE E, TOBIN, W. OLIVER · 2020 to 2024
$3.1MNCI NIH HHS K12 CA090628NCI NIH HHS P50 CA097274NINDS NIH HHS R01 NS113803
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedCladribineCombined Modality TherapyDisease ProgressionDrug EvaluationFemaleHistiocytosis, Langerhans-CellHumansKaplan-Meier EstimateMagnetic Resonance ImagingMaleMAP Kinase Signaling SystemMiddle AgedMutation, MissensePoint MutationBRAF protein, humanCladribineProto-Oncogene Proteins B-raf
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.